Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 2/20 | 0.43 |
| ▸ | FNTB | P49356 | 2/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18782968 | 0.88 | LMNA (0.50) | LMNALTA4HALDH1A1NPSR1FOLH1 | |
| SCHEMBL18782970 | 0.88 | LMNA (0.50) | LMNALTA4HALDH1A1NPSR1FOLH1 | |
| SCHEMBL18782952 | 0.88 | LMNA (0.50) | LMNALTA4HALDH1A1NPSR1FOLH1 | |
| SCHEMBL5332134 | 0.85 | LMNA (0.50) | LMNALTA4HALDH1A1NPSR1FOLH1 | |
| SCHEMBL29851702 | 0.83 | LMNA (0.51) | LMNALTA4HALDH1A1NPSR1FOLH1 | |
| SCHEMBL4572626 | 0.83 | LMNA (0.51) | LMNALTA4HALDH1A1NPSR1FOLH1 | |
| SCHEMBL4957057 | 0.83 | LMNA (0.51) | LMNALTA4HALDH1A1NPSR1FOLH1 | |
| SCHEMBL23319296 | 0.83 | LMNA (0.46) | LMNALTA4HALDH1A1NPSR1FOLH1 | |
| SCHEMBL18485886 | 0.83 | LMNA (0.46) | LMNALTA4HALDH1A1NPSR1FOLH1 | |
| SCHEMBL18485876 | 0.83 | LMNA (0.46) | LMNALTA4HALDH1A1NPSR1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | SEIWA KASEI COMPANY, LIMITED (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1584320-A1 | COSMETIC PREPARATION CONTAINING GLYCERYLAMINO ACID DERIVATIVE | Seiwa Kasei Company, Limited (JP) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | GLA, GPKOW, CUTA | LMNA 1546/4885LTA4H 1795/4885ALDH1A1 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.